Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epcoritamab + zanubrutinib + rituximab
- Development stage
- Phase 2
- Lead developer
- AbbVie
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral, Intravenous
01
Overview
Epcoritamab + zanubrutinib + rituximab (EZR) is a chemotherapy-free combination regimen currently under investigation in a Phase 2 clinical trial (NCT06563596) for patients with relapsed or refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL). The regimen is led by Dr. Reid Merryman at the Dana-Farber Cancer Institute. Epcoritamab is a bispecific antibody that binds to CD3 on T-cells and CD20 on B-cells, inducing T-cell-mediated killing of malignant B-cells. Zanubrutinib is a potent, selective Bruton tyrosine kinase (BTK) inhibitor that disrupts B-cell receptor signaling, while rituximab is a chimeric monoclonal antibody targeting CD20. This triple combination aims to achieve deep and durable remissions by simultaneously engaging the immune system and inhibiting key survival pathways in lymphoma cells.
- Brand names
- Tepkinly
- Other names
- EZR regimenEZR study
02
Targets
Beyond the preview
Go deeper on epcoritamab + zanubrutinib + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epcoritamab + zanubrutinib + rituximab.